A1020: Cancer Antigen 19-9 (CA 19-9)

Cancer Antigen 19-9 (CA 19-9) - Pancreatic & GI Tumor Marker

Cancer Antigen 19-9 (CA 19-9) is a carbohydrate tumor-associated antigen widely recognized as the primary biomarker for pancreatic cancer, and a valuable marker for other gastrointestinal malignancies. This product is derived from cell culture supernatant and manufactured to meet strict performance specifications.

CA 19-9 is essential for monitoring disease progression, evaluating therapeutic response, and calibrating diagnostic assays in pancreatic and GI oncology.

Specifications

• Source: Cell Culture Supernatant
• Buffer & pH: PBS Buffer, pH 7.4 ± 0.2
• Preservative: 0.1% Sodium Azide
• Filtration: 0.2 µm filtered
• Storage: -20°C or colder
• Protein Quantitation: 60,000-200,000 U/mL (cobas CA 19-9 Assay)*
• Purity Ratio: ≥600 U/mL/OD280*
• Total Protein: ≤200 O.D. Units (OD280)*

*Specific lot values may vary

Key Features

• Tested non-reactive for HIV 1/2, HBsAg, HCV, HIV-1 (NAT), and HCV (NAT) by current FDA methods
• Sourced from USDA-inspected U.S. abattoirs
• Cross-reactivity controlled: CA 15-3, CA 125, CEA, NSE all <20% of CA 19-9 concentration
• 0.2 µm filtered and formulated in PBS with sodium azide preservative
• For research use or manufacturing of non-injectable products only

Applications

• Development and calibration of immunoassays (ELISA, CLIA, LFA)
• Pancreatic and gastrointestinal cancer biomarker research
• Quality control materials for diagnostic kit production
• Therapy response monitoring and recurrence detection studies